Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2667-3371
  • E-ISSN: 2667-338X

Abstract

Introduction

Fixed-dose combination (FDC) drugs have emerged as a promising strategy to enhance patient compliance and simplify treatment regimens, especially in cases requiring multiple medications. Their growing use in clinical practice highlights their potential benefits in managing complex diseases. This review aims to evaluate the current challenges associated with FDCs, focusing on issues related to safety, efficacy, and regulatory oversight. Special attention is given to the recent ban on irrational FDCs by the Indian government.

Methods

A comprehensive literature review was conducted using scientific databases and policy reports. The review analyzed pharmacokinetic and pharmacodynamic concerns, manufacturing challenges, and regulatory frameworks governing FDC development and approval.

Results

FDCs reduce pill burden and improve adherence, but major concerns remain regarding dose inflexibility, adverse drug interactions, and the emergence of antimicrobial resistance. The 2024 ban on 156 FDCs in India underscores the need for rigorous safety evaluations and rational drug combinations. Technological advancements, such as 3D printing, show potential for producing personalized FDCs, but face limitations due to regulatory and material safety concerns.

Discussion

The findings emphasize the critical need for rational FDC formulation, as many banned combinations lacked therapeutic justification and posed safety risks. This aligns with existing literature highlighting pharmacokinetic incompatibilities and adverse drug reactions. However, the study is limited by its reliance on secondary data and the exclusion of non-English publications, which may restrict broader applicability.

Conclusion

To maximize the public health benefits of FDCs, stronger regulatory measures, evidence-based formulation practices, and pharmacogenetic screening are necessary. Incorporating FDC approval with WHO prequalification standards and implementing quality-by-design protocols can ensure the development of safe, effective, and patient-focused combination therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/adctra/10.2174/0126673371389705250825195039
2025-09-04
2026-04-20

  • From This Site

    /content/journals/adctra/10.2174/0126673371389705250825195039
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. GuoL. XiaoX. Guideline for the management of diabetes mellitus in the elderly in China (2024 Edition).Aging Med.20247155110.1002/agm2.12294 38571669
     [Google Scholar]
  2. KhanR. Socha-DietrichK. Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia.2018Available from: https://www.oecd.org/content/dam/oecd/en/publications/reports/2018/06/investing-in-medication-adherence-improves-health-outcomes-and-health-system-efficiency_3006fa8a/8178962c-en.pdf
  3. KwakyeA.O. KretchyI.A. PeprahP. MensahK.B. Factors influencing medication adherence in co-morbid hypertension and diabetes patients: A scoping review.Explor. Res. Clin. Soc. Pharm.20241310042610.1016/j.rcsop.2024.100426 38455671
     [Google Scholar]
  4. DevarbhaviH. AithalG. TreeprasertsukS. Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines.Hepatol. Int.202115225828210.1007/s12072‑021‑10144‑3 33641080
     [Google Scholar]
  5. LeeH.Y. ChenP.H. WangW.S. HuangY.M. WuT.T. Empowering ChatGPT with guidance mechanism in blended learning: Effect of self-regulated learning, higher-order thinking skills, and knowledge construction.Int. J. Educ. Technol. High. Educ.20242111610.1186/s41239‑024‑00447‑4
     [Google Scholar]
  6. PriftiK. Fosch-VillarongaE. Towards experimental standardization for AI governance in the EU.Comput. Law Secur. Rev.20245210595910.1016/j.clsr.2024.105959
     [Google Scholar]
  7. KobalavaZ. SafarovaA.F. TolkachevaV. Assessment of pulmonary congestion according to ultrasound and remote dielectric sensing (ReDS) in patients hospitalized with heart failure.Arq. Bras. Cardiol.2024121102024012810.36660/abc.20240128i 39536195
     [Google Scholar]
  8. Galdón Sanz-PastorA. Justel EnríquezA. Sánchez BaoA. Ampudia-BlascoF.J. Current barriers to initiating insulin therapy in individuals with type 2 diabetes.Front. Endocrinol.202415136636810.3389/fendo.2024.1366368 38559691
     [Google Scholar]
  9. WeiQ. ZhouJ. LiH. Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis.Front. Pharmacol.202314115608110.3389/fphar.2023.1156081 37033611
     [Google Scholar]
  10. AnsariM.I. DubeyN. GaneshpurkarA. Hepatoprotective potential of vanillic acid against isoniazid-rifampicin-induced liver toxicity.Asp Mol Med2025510008710.1016/j.amolm.2025.100087
     [Google Scholar]
  11. Luciani-GiacobbeL.C. LorenzuttiA.M. LitterioN.J. Ramírez-RigoM.V. OliveraM.E. Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid.Drug Deliv. Transl. Res.202111389490810.1007/s13346‑020‑00847‑9 32901368
     [Google Scholar]
  12. Zivari-MoshfeghF. JavanmardiF. NematollahiD. A comprehensive electrochemical study on anti-tuberculosis drug rifampicin. Investigating reactions of rifampicin-quinone with other anti-tuberculosis drugs, isoniazid, pyrazinamide and ethambutol.Electrochim. Acta202345714248710.1016/j.electacta.2023.142487
     [Google Scholar]
  13. KaranwadT. JorvekarS.B. MandalS. BorkarR.M. BanerjeeS. Profiling of 3-Formyl rifamycin (3-FR) from sintered fixed dose combinations (SDC) of rifampicin and isoniazid by using RP-HPLC, LC-ESI-QTOF and UPLC/MS/MS.Microchem. J.202419710986910.1016/j.microc.2023.109869
     [Google Scholar]
  14. ChattopadhyayP. GoyaryD. Modern medicine: Biomedical devices.Medical Gases, Radiopharmaceuticals, New Drug Discovery.Boca Raton, FloridaCRC Press202410.1201/9781003397854
     [Google Scholar]
  15. CorbinC.M. The government speech doctrine ate my class: First Amendment capture and curriculum bans.Stanford Law Rev.2024761473
     [Google Scholar]
  16. ChattopadhyayP. GoyaryD. Life Sciences Research to Product Development: Regulatory Requirement Transforming.Boca Raton, FloridaCRC Press2024110.1201/9781003398431
     [Google Scholar]
  17. KeanE.A. AdelekeO.A. Geriatric drug delivery — barriers, current technologies and the road ahead.J. Drug Target.202432101186120610.1080/1061186X.2024.2386626 39076049
     [Google Scholar]
  18. GodmanB. McCabeH.D. LeongT. Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries.Expert Rev. Pharmacoecon. Outcomes Res.202020112610.1080/14737167.2020.1734456 32237953
     [Google Scholar]
  19. KimD.W. WeonK.Y. Pharmaceutical application and development of fixed-dose combination: Dosage form review.J. Pharm. Investig.202151555557010.1007/s40005‑021‑00543‑x
     [Google Scholar]
  20. OnwuzuligboCC OnwuzuligboAU Fixed dose combination, a model therapy optimization strategy: A review.GSC Adv Res Rev202420210.30574/gscarr.2024.20.2.0296
     [Google Scholar]
  21. MahatoT.K. KushwahaR.S. SharmaS. BrahmbhattZ. PatelA. An investigation into the reasoning for the ban on fixed dosage combinations.Inter J Multid Res Growth Eval20245565766210.54660/.IJMRGE.2024.5.5.657‑662
     [Google Scholar]
  22. SavilleB.R. BurkhoffD. AbrahamW.T. Streamlining randomized clinical trials for device therapies in heart failure: Bayesian borrowing of external data.J. Am. Heart Assoc.202413303325510.1161/JAHA.123.033255 38258663
     [Google Scholar]
  23. MalikM.A. WaniM.Y. HashmiA.A. Combination therapy: Current status and future perspectives.Combination therapy against multidrug resistance.United StatesAcademic Press2020138
     [Google Scholar]
  24. ShanmugamP.S.T. ThangarajuP. SampathT. JagadeeswaranI. Significant and nonsignificant risk medical devices.ChamSpringer202410.1007/978‑3‑031‑52838‑5
     [Google Scholar]
  25. MirandaM.R.H. DubeyA. G S R, Charyulu RN. Fixed-dose combinations banned in India: Is it the right decision? An eye-opening review.Expert Opin. Drug Saf.2019181097798510.1080/14740338.2019.1651292 31374180
     [Google Scholar]
  26. ZoungranaS. OuattaraZ. TapsobaA. Acute hepatitis with the tramadol-paracetamol combination; About an observation at the Regional University Hospital Center of Ouahigouya in Burkina Faso and review of the literature.Gastroint Hepatol Dig Dis20247413
     [Google Scholar]
  27. MosesonD.E. TranT.B. KarunakaranB. AmbardekarR. HiewT.N. Trends in amorphous solid dispersion drug products approved by the U.S. Food and Drug Administration between 2012 and 2023.Int. J. Pharm. X2024710025910.1016/j.ijpx.2024.100259 38974024
     [Google Scholar]
  28. HensB. CorsettiM. BermejoM. LöbenbergR. GonzálezP.M. MitraA. “Development of fixed dose combination products” workshop report: Considerations of gastrointestinal physiology and overall development strategy.ChamSpringer2019
     [Google Scholar]
  29. SiddalingaiahS. Fugh-BermanA. Evergreened drugs or evergreened profits?J. Eval. Clin. Pract.20222861119112610.1111/jep.13695 35543377
     [Google Scholar]
  30. HahnJ.A. MaierM. Byakika-TusiimeJ. OyugiJ.H. BangsbergD.R. Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.J. Int. Assoc. Physicians AIDS Care (Chic.)200762838610.1177/1545109707299356 17537997
     [Google Scholar]
  31. SanuadeO.A. JacobsonT.A. QuintanaA. Process evaluation of a double‐blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra‐low‐dose treatment for hypertension within a federally qualified health center network (QUARTET USA).J. Am. Heart Assoc.202413103223610.1161/JAHA.123.032236 38156601
     [Google Scholar]
  32. KohlerS. AcharJ. MulderC. SitaliN. PaulN. Trends in the availability and prices of quality-assured tuberculosis drugs: A systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024.Global. Health20242015110.1186/s12992‑024‑01047‑7 38918859
     [Google Scholar]
  33. BogowiczP. MehtaA. ChoudharyS. Sales and regulatory status of fixed dose combination psychotropic drugs in India: A retrospective longitudinal study.J. Pharm. Policy Pract.2024171237208910.1080/20523211.2024.2372089 39558965
     [Google Scholar]
  34. JogaR. GadekarK.V. GandhiK. A comprehensive retrospective analysis of trends and strategic implications of 505(b)(2) approvals (2019–2023).Ther. Innov. Regul. Sci.202559479080710.1007/s43441‑025‑00775‑1 40323579
     [Google Scholar]
  35. RanjalkarJ. JhajR.J. ChandyS. Usage pattern of fixed-dose combinations at ICMR network of rational use of medicine centres across India: Recommendations for policymakers and prescribers.J. Assoc. Physicians India2023712303610.5005/japi‑11001‑0175 37354468
     [Google Scholar]
  36. BhattacharjeeS. BhattacharyaS. Uncovering the complexities of drug bans in India: Are key considerations being overlooked?Medical Journal of Dr DY Patil Vidyapeeth20241761149115310.4103/mjdrdypu.mjdrdypu_889_23
     [Google Scholar]
  37. VigneshM. GaneshG. Fixed dose combinations banned in India-a review.J Pharm Sci Res2020127987991
     [Google Scholar]
/content/journals/adctra/10.2174/0126673371389705250825195039
Loading
India’s 2024 Ban on Fixed-dose Combinations: Implications for Safety, Efficacy, and Regulatory Policy
Appl. Drug Resea., Clin. Trials and Regu. Affa. 11, E26673371389705 (2025); https://doi.org/10.2174/0126673371389705250825195039
/content/journals/adctra/10.2174/0126673371389705250825195039
/content/journals/adctra/10.2174/0126673371389705250825195039
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antimicrobial resistance; drug safety and efficacy; Fixed dose combination; Indian drug ban 2024; pharmacokinetic interactions; regulatory challenges

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test